Date
GLP-1 Shortage
Regarding: Anti-Diabetic Medication Shortages
MO HealthNet is aware of the continuing shortages of GLP-1 agonists in the marketplace. To avoid disruption in a participant’s diabetic therapy, please do not submit PA requests for non-preferred GLP-1 agonists if solely due to shortage or supply issues.
In the event you are unable to obtain the participant’s currently prescribed GLP-1 agonist through your wholesaler or another local pharmacy consider one of the following:
- Substitution with a different preferred GLP-1 agonist.
- Preferred GLP-1 agonists are Victoza® (liraglutide), Trulicity® (dulaglutide), and Byetta® (exenatide).
- For more information, please reference the GLP-1 Receptor Agonists & Combination Agents PDL Edit.
- Substitution with a preferred DPP-4 inhibitor (& combination) agent.
- GLP-1 agonists and DPP-4 inhibitors have a very similar mechanism of action.
- Preferred DPP-4 inhibitors & combination agents include:
- Janumet and Janumet XR (sitagliptin/metformin)
- Januvia (sitagliptin)
- Jentadueto (linagliptin/metformin)
- Kombiglyze XR (saxagliptin/metformin)
- Onglyza (saxagliptin)
- Tradjenta (linagliptin)
- For more information, please reference the DPP-IV Inhibitors & Combination Agents PDL Edit.
Requests for non-preferred GLP-1 agonists still require all prior authorization approval criteria to be met. Complete prior authorization criteria and the Preferred Drug Lists can be found on MO HealthNet’s website.